Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?
The Motley Fool
Eli Lilly acquired Boston-based biotech Orna Therapeutics for $2.4 billion to develop circular RNA-based gene therapies for autoimmune diseases. The deal represents Lilly's continued effort to fill its drug pipeline beyond its blockbuster GLP-1 drug tirzepatide. Orna's lead candidate ORN-252 uses innovative in vivo chimeric antigen receptor T-cell technology and is clinical trial-ready, though several years away from commercial sales.
Continue Reading